Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Spruce Biosciences, Inc.NASDAQ: SPRB
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$279K, compared with $451K a year earlier. Trailing-twelve-month other income / expenses was -$3.18M.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$279K or moves back toward the trailing-twelve-month quarterly average of -$795.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (2.45M) USD
- Year-over-year change
- -178.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.45M) | -178.7% |
| FY2024 | 2024-12-31 | 3.12M | -23.5% |
| FY2023 | 2023-12-31 | 4.07M | +269.4% |
| FY2022 | 2022-12-31 | 1.1M | +588.1% |
| FY2021 | 2021-12-31 | (226K) | — |
Other Income / Expenses vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 other income / expenses of -$3.18M is the 7th highest of the 9 companies compared; the peer median is -$687.83K.
- Its year-over-year change of -224.4% is the 7th highest of 9, against a peer median of -4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.31M | +7.4% | — | 6.3% | |
| LTM Mar 2026 | $1.32M | +83.1% | — | — | |
| LTM Mar 2026 | $561K | +2.7% | +24.9% | 1.7% | |
| LTM Mar 2026 | $24.01K | +122.3% | — | 1.7% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$1.4M | -1089.2% | — | — |
| LTM Mar 2026 | -$1.94M | -102.0% | — | 581.4% | |
| LTM Mar 2026 | -$3.18M | -224.4% | — | — | |
| LTM Mar 2026 | -$7.35M | -12.1% | — | 320.6% | |
| LTM Jun 2026 | -$9.04M | -6403.6% | — | 43.0% | |
| Peer median (excluding SPRB) | -$687.83K | -4.7% | +24.9% | 24.7% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| Weighted Avg Shares | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
| Weighted Avg Shares (Diluted) | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.